Liquid biopsy: current technology and clinical applications
M Nikanjam, S Kato, R Kurzrock - Journal of hematology & oncology, 2022 - Springer
Liquid biopsies are increasingly used for cancer molecular profiling that enables a precision
oncology approach. Circulating extracellular nucleic acids (cell-free DNA; cfDNA) …
oncology approach. Circulating extracellular nucleic acids (cell-free DNA; cfDNA) …
The next decade of immune checkpoint therapy
P Sharma, BA Siddiqui, S Anandhan, SS Yadav… - Cancer discovery, 2021 - AACR
Immune checkpoint therapy (ICT) can provide durable clinical responses and improve
overall survival. However, only subsets of patients with specific tumor types respond to ICT …
overall survival. However, only subsets of patients with specific tumor types respond to ICT …
[HTML][HTML] ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group
Circulating tumour DNA (ctDNA) assays conducted on plasma are rapidly developing a
strong evidence base for use in patients with cancer. The European Society for Medical …
strong evidence base for use in patients with cancer. The European Society for Medical …
Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single …
DY Oh, KH Lee, DW Lee, J Yoon, TY Kim… - The Lancet …, 2022 - thelancet.com
Background Immunotherapies have shown clinical activity in patients with advanced biliary
tract cancer, for which outcomes remain poor despite standard of care treatment with …
tract cancer, for which outcomes remain poor despite standard of care treatment with …
ctDNA guiding adjuvant immunotherapy in urothelial carcinoma
T Powles, ZJ Assaf, N Davarpanah, R Banchereau… - Nature, 2021 - nature.com
Minimally invasive approaches to detect residual disease after surgery are needed to
identify patients with cancer who are at risk for metastatic relapse. Circulating tumour DNA …
identify patients with cancer who are at risk for metastatic relapse. Circulating tumour DNA …
Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results
Checkpoint inhibitor (CPI) therapies provide limited benefit to patients with tumors of low
immune reactivity. T cell-inducing vaccines hold promise to exert long-lasting disease …
immune reactivity. T cell-inducing vaccines hold promise to exert long-lasting disease …
[HTML][HTML] Liquid biopsy for advanced NSCLC: a consensus statement from the international association for the study of lung cancer
Although precision medicine has had a mixed impact on the clinical management of patients
with advanced-stage cancer overall, for NSCLC, and more specifically for lung …
with advanced-stage cancer overall, for NSCLC, and more specifically for lung …
Detection and characterization of lung cancer using cell-free DNA fragmentomes
D Mathios, JS Johansen, S Cristiano, JE Medina… - Nature …, 2021 - nature.com
Non-invasive approaches for cell-free DNA (cfDNA) assessment provide an opportunity for
cancer detection and intervention. Here, we use a machine learning model for detecting …
cancer detection and intervention. Here, we use a machine learning model for detecting …
Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial
In patients with previously treated metastatic uveal melanoma, the historical 1 year overall
survival rate is 37% with a median overall survival of 7.8 months. We conducted a …
survival rate is 37% with a median overall survival of 7.8 months. We conducted a …
Perioperative ctDNA-based molecular residual disease detection for non–small cell lung cancer: a prospective multicenter cohort study (LUNGCA-1)
Purpose: We assessed whether perioperative circulating tumor DNA (ctDNA) could be a
biomarker for early detection of molecular residual disease (MRD) and prediction of …
biomarker for early detection of molecular residual disease (MRD) and prediction of …